OMER Omeros Corporation

13.6
+0.12  (+1%)
Previous Close 13.48
Open 13.84
Price To Book -6.77
Market Cap 737,190,407
Shares 54,205,177
Volume 538,266
Short Ratio
Av. Daily Volume 944,447
Stock charts supplied by TradingView

NewsSee all news

  1. Ranpak Appoints Former Amazon Global Treasurer to Its Board of Directors

    Ranpak Holdings Corp. ("Ranpak") (NYSE:PACK), a leading provider of environmentally sustainable, systems-based, product protection solutions for e-commerce and industrial supply chains, today announced that on March 3,

  2. Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results

    – Conference Call Today at 4:30 p.m. ET – Omeros Corporation (NASDAQ:OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics

  3. Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA

    – Results Surpass FDA-Agreed Efficacy Threshold – Omeros Corporation (NASDAQ:OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell

  4. Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020

    Omeros Corporation (NASDAQ:OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market

  5. Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors

    -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- Omeros Corporation (NASDAQ:OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Rolling BLA filing announced October 28, 2019. To be completed 1H 2020.
OMS721
Hematopoietic stem cell-associated TMA (HSCT-TMA)
Phase 3 trial enrollment initiated February 2018. Continues to enrol as of August 2019.
OMS721
IgA nephropathy
Phase 2 data released October 2016.
OMS721
Kidney disorders
Approved June 2, 2014.
Omidria
Cataract surgery
Phase 3 enrollment has opened - noted March 16, 2017.
OMS721
Atypical hemolytic uremic syndrome (aHUS)
Phase 1 data September 16, 2019 noted treatment was safe and well-tolerated.
OMS527
Nicotine Addiction

Latest News

  1. Ranpak Appoints Former Amazon Global Treasurer to Its Board of Directors

    Ranpak Holdings Corp. ("Ranpak") (NYSE:PACK), a leading provider of environmentally sustainable, systems-based, product protection solutions for e-commerce and industrial supply chains, today announced that on March 3,

  2. Omeros Corporation Reports Fourth Quarter and Year-End 2019 Financial Results

    – Conference Call Today at 4:30 p.m. ET – Omeros Corporation (NASDAQ:OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics

  3. Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA

    – Results Surpass FDA-Agreed Efficacy Threshold – Omeros Corporation (NASDAQ:OMER) today reports an update on clinical data from its pivotal trial of narsoplimab in the treatment of hematopoietic stem cell

  4. Omeros Corporation to Announce Fourth Quarter and Year-End 2019 Financial Results on March 2, 2020

    Omeros Corporation (NASDAQ:OMER) today announced that the company will issue its fourth quarter and year-end 2019 financial results for the period ended December 31, 2019, on Monday, March 2, 2020, after the market

  5. Omeros Corporation Appoints Former Amazon Treasurer Kurt Zumwalt to Board of Directors

    -- Zumwalt Also to Serve as Consultant, Bringing Extensive Capital Markets Background to Omeros -- Omeros Corporation (NASDAQ:OMER) today announced the appointment of Kurt Zumwalt, former global treasurer of

  6. myTomorrows and Omeros Corporation Collaborate to Provide an Expanded Access Program for Narsoplimab

    myTomorrows, a global health technology company, and Omeros Corporation (NASDAQ:OMER), an innovative biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein

  7. Omeros' Newly Presented GPR174 Immuno-oncology Data at ESMO Immuno-Oncology Congress Show Inhibition of Both Checkpoint and Tumor-Promoting Factors

    Omeros Corporation (NASDAQ:OMER) last week presented new data directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology (ESMO) 2019 Immuno-Oncology Congress in Geneva,

  8. Omeros Announces Full Exercise and Closing of Underwriter's Option to Purchase Additional Shares

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  9. Omeros to Present GPR174 Data at the European Society for Medical Oncology 2019 Immuno-Oncology Congress in Geneva

    Omeros Corporation (NASDAQ:OMER) today announced an upcoming presentation directed to its novel cancer immunotherapy target GPR174 at the European Society for Medical Oncology 2019 Immuno-Oncology Congress, which is

  10. Omeros Announces Pricing of Upsized Public Offering of Common Stock

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  11. Omeros Announces Proposed Public Offering of Common Stock

    Omeros Corporation (NASDAQ:OMER) ("Omeros"), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as

  12. Omeros Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy Patients Treated with Narsoplimab

    – 56 Percent of All Narsoplimab-Treated Patients Were Complete Responders by Primary Endpoint, Achieving Full Set of Response Criteria Agreed by FDA; 68 Percent Primary-Endpoint Complete Response Rate for Those Who

  13. Omeros' New GPR174 Immuno-oncology Data Presented at the American Association for Cancer Research Conference In Boston Now Available Online

    Omeros Corporation (NASDAQ:OMER) presented new GPR174 immuno-oncology data yesterday at the American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy in Boston, Massachusetts. The

  14. Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston

    -- GPR174 Deficiency Improves Outcomes in Animal Tumor Models -- Omeros Corporation (NASDAQ:OMER) today announced new findings on GPR174, its novel cancer immunotherapy target, demonstrating that GPR174-deficiency

  15. Omeros Corporation Reports Third Quarter 2019 Financial Results

    Conference Call Today at 4:30 p.m. ET Omeros Corporation (NASDAQ:OMER), a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for

  16. Omeros to Present GPR174 Data at Upcoming American Association for Cancer Research Conference on Tumor Immunology and Immunotherapy

    Omeros Corporation (NASDAQ:OMER) today announced an upcoming presentation entitled "Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances

  17. Omeros Scientists Win 2019 Prix Galien Research Award

    --Prestigious Prize Conferred for GPCR Program Discoveries-- Omeros Corporation (NASDAQ:OMER) today announced that three of its scientists––Alexander Gragerov, Ph.D., associate vice president of research, George A.

  18. Omeros Corporation to Announce Third Quarter 2019 Financial Results on November 12, 2019

    Omeros Corporation (NASDAQ:OMER), today announced that the company will issue its third quarter 2019 financial results for the period ended September 30, 2019, on Tuesday, November 12, 2019, after the market closes.

  19. Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain

    -- Study Demonstrates Opioid-Sparing Requirement of OMIDRIA for CMS Packaging Exclusion -- Omeros Corporation (NASDAQ:OMER) today announced that results of a prospective, controlled study showing that its FDA-approved

  20. Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA

    – Rolling Submission of the Remaining BLA Sections Continues On Track for Scheduled Completion 1H 2020 – Omeros Corporation (NASDAQ:OMER) has submitted the first sections of the rolling submission of its Biologics

  21. Product-Specific J-Code for Omeros' OMIDRIA® is Now in Effect

    Omeros Corporation (NASDAQ:OMER) today announced that the product-specific J-code for OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% is now effective. OMIDRIA is Omeros' commercial drug marketed

  22. Omeros Announces Publication of Study Showing that Inhibition of MASP-2, the Key Enzyme of the Complement System's Lectin Pathway, Protects Against Renal Injury Caused by Proteinuria

    Omeros Corporation (NASDAQ:OMER) today announced publication of study results showing that inhibition of mannan-binding lectin-associated serine protease-2 (MASP-2) protects against renal injury caused by proteinuria

  23. Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addiction

    -- Phase 1 study results show excellent safety and PK profile consistent with once-daily dosing -- Omeros Corporation (NASDAQ:OMER) today announced positive results from its Phase 1 study with the lead compound in its

  24. FDA Confirms Omeros' Schedule for Rolling Review of the Company's BLA for Narsoplimab in the Treatment of HSCT-TMA

    – Omeros Remains On Track to Initiate the Submission Next Quarter – Omeros Corporation (NASDAQ:OMER) announced that the United States Food and Drug Administration (FDA) agreed with the company's proposed schedule for

  25. Omeros Discovers New Cancer-Immunity Pathways Controlled by GPR174

    -- The Company's GPR174 Inhibitors Enhance Anti-Tumor Activities of Adenosine Pathway Inhibitors by up to 25-Fold -- Omeros Corporation (NASDAQ:OMER) today announced a new approach to cancer immunotherapy that targets

  26. Omeros to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    Omeros Corporation (NASDAQ:OMER), today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, will present at the H.C. Wainwright 21st Annual Global Investment Conference in New York next